ESTRO 2020 Abstract book

S179 ESTRO 2020

Focal boosting of the tumor up to 95Gy in patients with intermediate and high risk prostate cancer does not deteriorate patient reported QoL compared to standard treatment, provided the same dose constraints to organs at risk are maintained. This is in line with previously published (physician reported) toxicity outcomes in the FLAME trial at two year follow-up. OC-0316 Effect of exercise during ADT and radiation on patient-reported toxicity in men with prostate cancer O. Schumacher 1,2 , D.A. Galvão 1,2 , D.R. Taaffe 1,2,3 , N. Spry 1,4,5 , D.J. Joseph 1,4,6 , R.U. Newton 1,2,3,7 1 Edith Cowan University, Exercise Medicine Research Institute, Joondalup, Australia ; 2 Edith Cowan University, School of Medical and Health Sciences, Joondalup, Australia ; 3 University of Queensland, School of Human Movement and Nutrition Sciences, Brisbane, Australia ; 4 University of Western Australia, Faculty of Medicine, Nedlands, Australia ; 5 GenesisCare, Genesis CancerCare, Joondalup, Australia ; 6 Sir Charles Gairdner Hospital, Department of Radiation Oncology, Nedlands, Australia ; 7 University of Hong Kong, Institute of Human Performance, Hong Kong, China Purpose or Objective In addition to clinical factors, physical inactivity has been associated with higher levels of late pelvic symptoms in men with prostate cancer after treatment with radiotherapy. The aim of this study was to investigate the effect of a structured multicomponent exercise program that contained aerobic and resistance training as well as impact loading on the incidence and severity of symptoms commonly resulting from androgen deprivation therapy (ADT) and radiotherapy for prostate cancer. Material and Methods We performed a secondary analysis of pooled data from two randomised controlled trials that investigated the role of exercise on treatment-related side-effects in men with prostate cancer receiving ADT. Patients were included in the secondary analysis if they had undergone radiotherapy during the course of the exercise intervention in addition to ADT. Patient-reported quality of life, functional and symptom scales were assessed before and after 6 months of exercise (EX, n = 72) or usual care/control (CON, n = 43) using the EORTC QLQ-C30 and PR25 questionnaires. The duration of ADT prior to enrolment and the timing of radiotherapy in relation to the assessment at 6 months varied among participants. Exercise was supervised and undertaken 2-3 days per week at a moderate to high intensity. A two-way (group x time) repeated-measures ANOVA was performed to analyse changes in outcome variables over time. Follow-up tests were performed if the interaction or main effect for time was significant. Results One-hundred and fifteen men with prostate cancer on ADT, aged 47-84 years, who underwent radiotherapy were included in the secondary analysis. There was a significant interaction for physical functioning (p=0.033) and a significant main effect for time in fatigue (p=0.042), diarrhoea (p<0.001), urinary (p=0.001), bowel (p=0.002), and hormonal treatment-related symptoms (p<0.001). In CON, physical functioning decreased (~4 points) and fatigue increased (~7 points), whereas no significant changes were observed in EX. Urinary, bowel and hormonal treatment-related symptoms significantly increased in both groups (~7 vs. 9, ~4 vs. 3, and ~8 vs. 6 points for EX vs. CON, respectively), whereas diarrhoea significantly increased only in EX (~10 points) compared to a non-

significant increase in CON (~5 points). Similar to physical functioning, there was a significant interaction for sexual activity (p=0.021), where sexual activity was maintained in EX and showed a trend to decrease in CON (7 points, p=0.086). Conclusion Exercise during concomitant hormone and radiation treatment for men with prostate cancer mitigates adverse changes in patient-reported physical functioning, fatigue and sexual activity. There was no difference in increased patient-reported urinary, bowel and hormonal treatment- related symptoms between those who exercised and controls. OC-0317 Risk factors for persistent late fatigue after radiochemotherapy in cervical cancer (EMBRACE study) S. Smet 1,2 , K. Tanderup 3 , R. Nout 4 , I. Jürgenliemk-Schulz 5 , S. Spampinato 3 , C. Chargari 6 , J. Lindegaard 3 , U. Mahantshetty 7 , A. Strudza 1 , M. Schmid 1 , P. Hoskin 8 , B. Segedin 9 , K. Bruheim 10 , B. Rai 11 , F. Huang 12 , E. Van Der Steen-Basanik 13 , R. Cooper 14 , E. Van Limbergen 15 , M. Sundset 16 , R. Pötter 1 , K. Kirchheiner 1 1 Medical University of Vienna, Department of Radiation Oncology- Comprehensive Cancer Center, Vienna, Austria ; 2 Algemeen Ziekenhuis Turnhout, Department of Radiation Oncology, Turnhout, Belgium ; 3 Aarhus University Hospital, Department of Oncology, Aarhus, Denmark ; 4 Leiden University Medical Center, Department of Radiation Oncology, Leiden, The Netherlands ; 5 University Medical Centre Utrecht, Department of Radiation Oncology, Utrecht, The Netherlands ; 6 Gustave-Roussy, Department of Radiotherapy, Villejuif, France ; 7 Tata Memorial Hospital, Department of Radiation Oncology, Mumbai, India ; 8 Mount Vernon Hospital, Cancer Centre, London, United Kingdom ; 9 Institute of Oncology, Department of Radiotherapy, Ljubljana, Slovenia ; 10 The Norwegian Radium Hospital- Oslo University Hospital, Department of Oncology, Oslo, Norway ; 11 Postgraduate Institute of Medical Education and Research, Department of Radiotherapy and Oncology, Chandigarh, India ; 12 Cross Cancer Institute and University of Alberta, Department of Oncology, Edmonton, Canada ; 13 Arnhem Radiotherapy Institute, Department of Radiotherapy, Arnhem, The Netherlands ; 14 St James’s University Hospital, Leeds Cancer Centre, Leeds, United Kingdom ; 15 University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium ; 16 St. Olavs Hospital, Clinic of Oncology and Women's Clinic, Trondheim, Norway Purpose or Objective Fatigue, characterized by a state of generalized weakness, is a common symptom after cancer treatment, with substantial impact on patient quality of life. Several patient-related risk factors, such as depression, baseline fatigue, anemia and inflammatory parameters are established, while radiotherapy-specific risk factors remain unclear. The purpose of this analysis is to evaluate patient- and treatment-related risk factors for persistent late fatigue within the prospective, observational, multi- center EMBRACE study (An intErnational study on MRI- guided BRachytherapy in locally advanced CErvical cancer; www.embracestudy.dk). Material and Methods From 2008-2015, 1416 patients with locally advanced cervical cancer participated in the study and received radiochemotherapy and MRI-guided adaptive brachytherapy (BT) per GEC-ESTRO guidelines. Fatigue was prospectively assessed (CTCAE v.3) at baseline and during